Skip to content
BR.31 & ASCO GU '26 episode artwork

Mar 5, 2026 18 min

BR.31 & ASCO GU '26

from OncoPharm Hosted by John Bossaer

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022) Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

BR.31 & ASCO GU '26

0:00 18:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 18 minutes long.

When was this OncoPharm episode published?

This episode was published on March 5, 2026.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.